Calidi Biotherapeutics earnings release, August 13, 2026

Calidi Biotherapeutics, Inc. (CLDI) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Calidi

Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent

Business

Highlights

SAN

DIEGO, August 13, 2026 -

Calidi

Biotherapeutics,

Inc. (NYSE American: CLDI)

(“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported financial and operating results for the three months ended June 30, 2026, and reviewed recent business highlights.

“Throughout the second quarter,

Calidi continued to advance its RedTail platform and redefine the potential of oncolytic viruses and genetic medicine,” said Eric Poma,

Ph.D.,

Calidi

Biotherapeutics CEO. “We anticipate CLD-401, the lead drug candidate from our RedTail platform, entering the clinic during the first quarter of 2027. In addition, we have expanded what the RedTail platform can do with our new approach of in situ

T-cell engagers.”

Second

Quarter 2026 and Recent

Business

Developments

Second

Quarter 2026 Financial Results

Calidi reported a net loss attributable to common stockholders of $4.2 million, or $2.94 per share, for the second quarter of

2026, compared with a net loss attributable to common stockholders of $5.7 million, or $31.75 per share, for the same period in 2025.

Prior-period share and per-share amounts have been adjusted to reflect the Company’s 1-for-16 reverse stock split completed in July 2026.

Research and development expenses were $2.6 million for the second quarter of 2026, unchanged from the second quarter of 2025.

General and administrative expenses were $1.6 million for the second quarter of

2026, compared with

$3.1 million for the comparable period in 2025.

The

Company had $4.1 million in cash and $0.2 million in restricted cash as of June 30, 2026, compared with

$5.6 million in cash and $0.2 million in restricted cash as of December 31, 2025.

About

Calidi Biotherapeutics

Calidi

Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.

CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.

Calidi

Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s

Corporate Presentation here.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except per share data)

Three Months Ended June 30, – 2026 – (Unaudited)Three Months Ended June 30, – 2025 – (Unaudited)
OPERATING EXPENSESResearch and development2,5582,593
OPERATING EXPENSESGeneral and administrative1,5923,071
OPERATING EXPENSESTotal operating expense4,1505,664
OPERATING EXPENSESLoss from operations-4,150-5,664
OTHER INCOME (EXPENSE), NETInterest expense-29-29
OTHER INCOME (EXPENSE), NETInterest expense – related party-6-23
OTHER INCOME (EXPENSE), NETChange in fair value of other liabilities and derivatives-1-18
OTHER INCOME (EXPENSE), NETChange in fair value of other liabilities and derivatives – related party-1
OTHER INCOME (EXPENSE), NETOther income (expense), net31-22
OTHER INCOME (EXPENSE), NETTotal other expense, net-5-93
OTHER INCOME (EXPENSE), NETLOSS BEFORE INCOME TAXES-4,155-5,757
OTHER INCOME (EXPENSE), NETIncome tax provision-5-4
OTHER INCOME (EXPENSE), NETNET LOSS-4,160-5,761
OTHER INCOME (EXPENSE), NETNet loss attributable to noncontrolling interest-46
OTHER INCOME (EXPENSE), NETNET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST-4,160-5,715
OTHER INCOME (EXPENSE), NETNET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS-4,160-5,715
OTHER INCOME (EXPENSE), NETNet loss per share; basic and diluted-2.94-31.75
OTHER INCOME (EXPENSE), NETWeighted average common shares outstanding; basic and diluted1,416180

Balance Sheet

June 30, 2026 — ( In thousands, except for par value data )

June 30, 2026 – (Unaudited)December 31, 2025
CURRENT ASSETSCash4,0715,600
CURRENT ASSETSPrepaid expenses and other current assets1,357656
CURRENT ASSETSTotal current assets5,4286,256
NONCURRENT ASSETSMachinery and equipment, net775781
NONCURRENT ASSETSOperating lease right-of-use assets, net9921,682
NONCURRENT ASSETSOther noncurrent assets9138
NONCURRENT ASSETSTOTAL ASSETS7,2048,857
CURRENT LIABILITIESAccounts payable930595
CURRENT LIABILITIESRelated party accounts payable18
CURRENT LIABILITIESAccrued expenses and other current liabilities1,1311,276
CURRENT LIABILITIESRelated party accrued expenses and other current liabilities530
CURRENT LIABILITIESFinance lease liability, current167111
CURRENT LIABILITIESOperating lease right-of-use liability, current1,0091,405
CURRENT LIABILITIESTotal current liabilities3,2373,935
NONCURRENT LIABILITIESOperating lease right-of-use liability, noncurrent5277
NONCURRENT LIABILITIESFinance lease liability, noncurrent161171
NONCURRENT LIABILITIESPromissory note600600
NONCURRENT LIABILITIESWarrant liability63107
NONCURRENT LIABILITIESRelated party warrant liability58
NONCURRENT LIABILITIESTOTAL LIABILITIES4,0715,098
NONCURRENT LIABILITIESTOTAL EQUITY3,1333,759
NONCURRENT LIABILITIESTOTAL LIABILITIES AND TOTAL EQUITY7,2048,857
Full release

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States

Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”

“possible,” “potential,” “predicts,” “project,” “should,” “towards,”

“would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, the Company’s plans strategies, priorities and key operational initiatives for fiscal year 2026 and 2027, including the Company’s plan to dose the first patient in a phase

1 trial in Q1 2027, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates; and, with respect to the Company’s fiscal year 2026 and 2027 initiatives, including the timing and ability to open a phase 1 clinical study in Q1 2027, the risk that actual results may differ materially due to, among other things, the timing, cost and results of research and development activities and preclinical studies; interactions with, and the timing and substance of feedback from, regulatory authorities (including that any preliminary interactions with the FDA may not be indicative of future outcomes or regulatory success); changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s... (truncated)mended or supplemented by other reports we file with the

SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investors

Contact:

IR@calidibio.com

Media

Contact:

PR@calidibio.com

CALIDI

BIOTHERAPEUTICS, INC.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.